文章摘要
周 云,吴 弘,张 超,缪志静,施珊岚.阿托伐他汀治疗冠心病的临床疗效及机制研究[J].,2017,17(9):1692-1695
阿托伐他汀治疗冠心病的临床疗效及机制研究
Clinical Effects and Mechanisms of Atorvastatin on the Coronary Heart Disease
投稿时间:2016-11-04  修订日期:2016-11-21
DOI:10.13241/j.cnki.pmb.2017.09.024
中文关键词: 冠心病  阿托伐他汀  炎症因子  氧化应激  血管内皮功能
英文关键词: Coronary heart disease  Atorvastatin  Inflammation factors  Oxidative stress  Endothelial function
基金项目:上海市自然科学基金项目(10R13089)
作者单位
周 云 第二军医大学附属长海医院 心内科 上海 200433上海市宝山区中西医结合医院 心内科 上海 201999 
吴 弘 第二军医大学附属长海医院 心内科 上海 200433 
张 超 上海市宝山区中西医结合医院 心内科 上海 201999 
缪志静 上海市宝山区中西医结合医院 心内科 上海 201999 
施珊岚 上海市宝山区中西医结合医院 心内科 上海 201999 
摘要点击次数: 524
全文下载次数: 251
中文摘要:
      摘要 目的:探讨阿托伐他汀治疗冠心病的临床疗效及其可能机制。方法:按照抽签法将170例冠心病患者分为对照组(n=85)及研究组(n=85),对照组予以常规治疗,研究组在对照组基础上使用阿托伐他汀治疗,比较两组治疗前后血清炎症因子[肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)、C反应蛋白(CRP)]水平、氧化应激水平[血清丙二醇(MDA)、超氧化物歧化酶(SOD)水平]、血管内皮功能[血清一氧化氮(NO)、内皮素-1(ET-1)水平]、血脂水平及心功能的变化。结果:治疗后,研究组患者血清TNF-α、MMP-9、CRP、MDA、ET-1 、总胆固醇(TC)、甘油三脂(TG)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)水平均显著低于对照组,而血清SOD、NO、高密度脂蛋白(HDL-C)左心室射血分数(LVEF)水平均显著高于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀可显著提高冠心病患者的心功能,可能与其有效抑制炎症、氧化应激和降低血脂水平有关。
英文摘要:
      ABSTRACT Objective: To study the clinical effects and mechanisms of atorvastatin on the coronary heart disease. Methods: 170 patients with coronary heart disease were divided into the control group (n=85) and research group (n=85) according to the method of lot- tery. The inflammation factor [tumor necrosis factor-α(TNF-α), matrix metalloproteinases-9 (MMP-9) and c-reactive protein (CRP)] lev- els, oxidative stress [Malondialdehyde (MDA), superoxide dismutase (SOD)] levels, endothelial function[Serum nitric oxide (NO) and endothelin-1 (ET-1) levels], blood lipids and heart function were compared between two groups before and after treatment. Results: After treatment, the serum TNF alpha, MMP-9, CRP, MDA, ET-1, total cholesterol (TC), triglycerides (TG), left ventricular end-diastolic di- ameter (LVEDD), left ventricular end systolic diameter (LVESD) levels of research group were significantly lower than those of the con- trol group, but the serum SOD, NO, high-density lipoprotein (HDL-C), left ventricular ejection fraction (LVEF) levels of research group were significantly higher than those of the control group(P<0.05). Conclusion: Atorvastatin could significantly improve the cardiac func- tion of patients with coronary heart disease, which might be related to the inhibition of inflammation, oxidative stress and reduction of blood lipid levels.
查看全文   查看/发表评论  下载PDF阅读器
关闭